Carlsmed, INC

Carlsmed, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of two Class I directors and the ratification of its independent auditor.

Carlsmed, a medical technology company, announced robust financial results for Q4 and full year 2025, driven by significant revenue growth and gross margin expansion.

Carlsmed, a medical technology company, announced preliminary and unaudited revenue for Q4 2025 and full year 2025, showing significant growth.

Carlsmed, Inc. announced robust third-quarter 2025 financial results, including 98% year-over-year revenue growth, and raised its full-year revenue guidance.

Carlsmed, Inc. has secured a new $50.0 million credit facility from Customers Bank, amending existing loan terms and reducing the number of shares underlying warrants held by the bank.

Carlsmed, Inc. reported a 99% year-over-year revenue increase to $12.1 million in Q2 2025, driven by its AI-enabled aprevo platform, and reaffirmed full-year guidance.

Carlsmed, Inc. reports significant revenue growth and gross margin improvement in Q3 2025, driven by increased adoption of its aprevo Technology Platform and successful IPO, despite continued operating losses.

Carlsmed, Inc. announced significant revenue growth and a successful $93.5 million IPO, while continuing to expand its AI-enabled spine surgery platform and address increasing net losses.

Carlsmed, Inc. achieved significant revenue growth and expanded its AI-enabled personalized spine surgery platform into cervical fusion, backed by strong clinical evidence and favorable reimbursement updates.

Carlsmed CEO Michael Cordonnier executed a cashless exercise of stock options and sold shares to cover costs, while also exercising additional options.

Carlsmed, Inc.'s Chief Commercial Officer, William Scott Durall, was granted 44,977 restricted stock units, vesting over three years.

Carlsmed's Chief IP Officer and Director, Niall Casey, acquired 44,977 restricted stock units, increasing his beneficial ownership to 982,562 shares.

CARLSMED, Inc. CEO and President Michael Cordonnier was granted 117,316 restricted stock units, vesting over three years.

CARLSMED, Inc.'s CFO and Treasurer, Leonard M. Greenstein, acquired 44,977 shares of common stock through a restricted stock unit grant.

B Capital Group Management and its affiliated funds significantly increased their beneficial ownership in Carlmed, Inc. to over 8.3 million common shares following automatic conversions of preferred stock and a direct purchase at the company's initial public offering.

Carlsmed, Inc. has issued a proxy statement announcing its 2026 Annual Meeting of Stockholders, scheduled for June 3, 2026, to elect directors and ratify auditor appointment.

Carlsmed, a medical technology company specializing in AI-enabled personalized spine surgery, is pursuing an initial public offering of 6.7 million shares, aiming to raise approximately $88.3 million to fuel commercialization and R&D, particularly for its planned 2026 cervical spine fusion market entry.

Carlsmed, Inc., a medical technology company pioneering AI-enabled personalized spine surgery solutions, has filed its S-1 registration statement for an initial public offering, showcasing significant revenue growth and positive clinical outcomes for its aprevo Technology Platform.

B Capital Group and its affiliated entities have reported a combined beneficial ownership of 27.8% in CARLSMED, INC.'s common stock as of September 30, 2025.

U.S. Venture Partners and its affiliates, including managing partner Casey M. Tansey, have disclosed a combined beneficial ownership of up to 22.0% in Carlsmed, Inc. common stock.

Michael Cordonnier has reported a beneficial ownership of 5.9% of Carlsmed, Inc.'s common stock following a recent reverse stock split.